Wall Street is negative on Cellect Biotechnology Ltd - ADR (APOP). On average, analysts give the stock a Strong Sell rating. The average price target is $, which means analysts expect the stock to fall by -100.00% over the next twelve months.
That average ranking earns the stock an Analyst Rating of 0, which is better than 0% of stocks based on data compiled by InvestorsObserver.
Why are Analyst Ratings Important?
A company's financial statements are a significant factor weighted by experts when analyzing a company's health. Beyond just the numbers, analysts follow specific industries closely and are able to gain a detailed understanding of how a storm in one part of the world can shutdown supply chains leading to a change in consumption across the globe. This knowledge allows investors to respond to potential changes in the market before they are revealed in a quarterly annoucement.
Investors Observer averages the ratings across all these analysts and percentile ranks those averages. This allows you to compare stocks in greater detail than the usual five-tiered system used amongst the majority of investors.
What's Happening With Cellect Biotechnology Ltd - ADR Stock Today?
Cellect Biotechnology Ltd - ADR (APOP) stock is trading at $3.40 as of 11:46 AM on Friday, Jun 26, a rise of $0.11, or 3.34% from the previous closing price of $3.29. The stock has traded between $3.23 and $3.60 so far today. Volume today is more active than usual. So far 522,673 shares have traded compared to average volume of 186,492 shares.